- Currently receiving or previously received monoclonal antibodies, immunomodulatory therapy, chemotherapy, radiation, or radioimmunotherapy within 4 weeks prior to study treatment, or has not recovered (i.e., less than or equal to Grade 1 or at baseline) from non-hematologic adverse events due to a previously administered agent.